China Nuokang Bio-Pharmaceutical Inc. is a leading, fully integrated, profitable biopharmaceutical company focused on researching, developing, manufacturing and marketing hematological and cardiovascular products. We sell a portfolio of fourteen products, which includes principal products Baquting®, a flagship hemocoagulase, and Aiduo®, a cardiovascular stress imaging agent. Our product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention.

Developed in-house and launched in 2001, Baquting, our flagship product, is China's leading hemocoagulase for the treatment or prevention of bleeding. Through September 30, 2009, we had sold an aggregate of over 38 million units of Baquting to our end-customer base of over 2,400 hospitals across China.

Our end-customer base includes approximately 80% of the Class 3A hospitals in major Chinese cities. Our sales force consisted of 24 direct sales offices with 300 sales personnel, complemented by 16 third-party marketing agents with over 200 sales personnel. We employ a physician-targeted marketing model, and our sales and marketing activities receive strong academic support from a specialist network comprising approximately 100 national key opinion leaders and physicians in various clinical areas.